Lipiodol Ultra Fluide

Phase 3Small molecule

DDafne Balemans

Lipiodol Ultra Fluide is one of 4 small molecule programs targeting Flushing. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

FlushingActive, not recruiting

FlushingPhase 3

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Flushing

#DrugCompanyPhaseTrials

Xylocaine

MMEDRx USA, Inc.

Approved

1 2

Lipiodol Ultra Fluide

DDafne Balemans

Phase 3

1 3

Prograf

VVeloxis Pharmaceuticals

Preclinical

1 4

Imigran

DDanish Headache Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Post-ApprovalActive, not recruiting

Flushing

NCT04379973

Clinical

Trials by Indication[1]

Flushing1 trial

Live Birth After Additional Tubal Flushing With Oil-based Contrast Versus no Additional Flushing:

Active, not recruiting·DDafne Balemans·Phase 4·NCT04379973·736 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lipiodol Ultra Fluide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lipiodol Ultra Fluide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lipiodol Ultra Fluide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dafne Balemans company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: DDafne Balemans

Lipiodol Ultra Fluide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Flushing1 trial

References

Drug Info

Quick Facts

Related News